Coronavirus Update: Brii Files US EUA For Antibody Combo
Plus, Wider Japan Ronapreve Use Sought
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.
You may also be interested in...
Pfizer gets European Commission approval for Paxlovid after a positive CHMP opinion, while Moderna started a Phase II study of its Omicron-specific vaccine candidate. Meanwhile, China's Junshi enters into a new oral antiviral collaboration while Daiichi Sankyo investigates its mRNA vaccine contender as a booster shot.
Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.
While new oral COVID-19 drugs are commanding the headlines, a little-known Chinese biotech is pushing ahead with an intravenous small molecule antiviral candidate now moving towards Phase II/III US trials, its CEO tells Scrip.